Four questions were posed about multiple sclerosis (MS) at the 2011 Charcot Lecture, Oct. 22, 2011. 1. The Male/Female Disparity: Why are women developing MS so much more frequently than men? 2. Neuronal and Glial Protection: Are there guardian molecules that protect the nervous system in MS? 3. Predictive Medicine: With all the approved drugs, how can we rationally decide which one to use? 4. The Precise Scalpel vs. the Big Hammer for Therapy: Is antigen-specific therapy for demyelinating disease possible? To emphasize how our views on the pathogenesis and treatment of MS are evolving, and given the location of the talk in Amsterdam, Piet Mondrian’s progressive interpretations of trees serve as a heuristic.
Pier Mondrian, AVOND (evening): The Red Tree, 1912.
2.
OrtonSMHerreraBMYeeIM. Sex ratio of multiple sclerosis in Canada: A longitudinal study. Lancet2006; 5: 932–936.
3.
NoonanCWKathmanSJWhiteMCPrevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology2002; 58: 136–138.
4.
DunnSOusmanSSobelRA. Peroxisome proliferator-activated receptor (PPAR)-α expression in T cells mediates gender differences in development of T cell-mediated autoimmunity. J Exp Med2007; 204: 321–330.
5.
Lovett-RackeAEHussainRZNorthropS. Peroxisome proliferators-activated receptor α agonists as therapy for autoimmune disease. J Immunol2004; 172: 5790–5798.
6.
ZhangMARegoDMoshkovaM. Peroxisome proliferator-activated receptors (PPAR)-α and -γ regulate IFNγ and IL-17A production by human T cells in a sex-specific way. Proc Natl Acad Sci U S A2012; 109: 9505–9510.
7.
Piet Mondrian, The Grey Tree, 1911.
8.
ChabasDBaranziniSMitchellD. The influence of the pro-inflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science2001; 294: 1731–1735.
9.
LockCHermansGPedottiR. Gene microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med2002; 8: 500–508.
10.
HanMHHwangSRoyDB. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature2008; 451: 1076–1081.
11.
HanMHLundgrenDHJaiswalS. Janus-like opposing roles of CD47 in autoimmune brain inflammation. J Exp Med2012; 209: 1325–1334.
HoPKanterJJohnsonAM. Identification of naturally occurring fatty acids of the myelin sheath that resolve neuroinflammation. Sci Transl Med2012; 4: 137ra73.
14.
BhatRAxtellRMitraA. Inhibitory role for GABA in autoimmune inflammation.Proc Natl Acad Sci U S A2010; 107: 2580–2585.
15.
OusmanSSTomookaBHvan NoortJM. Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Nature2007; 448: 474–479.
16.
RansohoffRMInflammatory disease: Assault on the guardian. Nature2007; 448: 421–422.
17.
RothbardJBKurnellasMPBrownellS. Therapeutic effects of systemic administration of the chaperone alpha B crystallin associated with binding proinflammatory plasma proteins. J Biol Chem2012; 287: 9708–9721.
18.
KurnellasMPBrownellSESuL. Chaperone activity of small heat shock proteins underlies therapeutic efficacy in experimental autoimmune encephalomyelitis. J Biol Chem2012; 287: 36423–36434. Epub 6September2012.
19.
van NoortJMvan SechelACBajramovicJJ. The small heat shock protein αB crystallin as a candidate autoantigen in MS. Nature1995; 375: 798–801.
20.
SteinmanLPresenting an odd autoantigen. Nature1995; 375: 739–740.
21.
Pangratz-FuehrerSKaurKOusmanSS. Functional rescue of experimental ischemic optic neuropathy with αB-crystallin. Eye (Lond)2011; 25: 809–817.
22.
AracABrownellSERothbardJB. Systemic augmentation of alphaB-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune modulation. Proc Natl Acad Sci U S A2011; 108: 13287–13292.
23.
VelottaJBKimuraNChangSH. αB-crystallin improves murine cardiac function and attenuates apoptosis in human endothelial cells exposed to ischemia-reperfusion. Ann Thorac Surg2011; 91: 1907–1913.
24.
GrantJLBou GhosnEEAxtellRC. Unexpected therapeutic benefit from peripheral administration of amyloid-β in TH1 and TH17 versions of experimental autoimmune encephalomyelitis. Sci Transl Med2012; 4: 145ra105.
25.
WeingerJGDaviesPAckerCM. Mice devoid of Tau have increased susceptibility to neuronal damage in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. J Neuropathol Exp Neurol2012; 71: 422–433.
26.
GourdainPBalleriniCNicotAB. Exacerbation of experimental autoimmune encephalomyelitis in prion protein (PrPc)-null mice: Evidence for a critical role of the central nervous system. J Neuroinflammation2012; 9: 25.
27.
CorriganFVinkRBlumbergsPC. sAPPα rescues deficits in amyloid precursor protein knockout mice following focal traumatic brain injury. J Neurochem2012; 122: 208–220.
28.
Piet Mondrian, The Flowering Apple Tree, 1912.
29.
LamDMKSteinmanLUptake of gamma-aminobutyric acid in the goldfish retina. Proc Natl Acad Sci U S A1971; 68: 2777–2781.
30.
AxtellRCde JongBABonifaceK. T helper type 1 and 17 cells determine efficacy of IFN-β in multiple sclerosis and experimental encephalomyelitis. Nature Med2010; 16: 406–412.
31.
BushnellSEZhaoZStebbinsCC. Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing–remitting MS. Neurology2012; 79: 531–537.
32.
HartungHPSteinmanLGoodinDS. IL-17F Does Not Predict Response to Interferon-Ä in Multiple Sclerosis Patients. Arch Neurol2012 in press.
33.
LeeLFAxtellRTuGH. IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosis. Sci Transl Med2011; 3: 93ra68.
34.
SweeneyCMLonerganRBaseoSA. IL-27 mediates the response to IFN-b therapy in multiple sclerosis patients by inhibiting Th17 cells. Brain Behav Immun2011; 25: 1170–1181.
35.
Dhib-JalbutSSumandeepSValenzuelaR. Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study. J Neuroimmunol. Epub ahead of print 18September2012. DOI: 10.1016/j.jneuroim. 2012.08.012.
36.
YednockTCannonCFritzL. Prevention of experimental autoimmune encephalomyelitis by antibodies against a4b1 integrin. Nature1992; 356: 63–66.
37.
SteinmanLBlocking adhesion molecules as therapy for multiple sclerosis: Natalizumab. Nat Rev Drug Discov2005; 4: 510–519.
38.
SteinmanLThe discovery of natalizumab, a potent therapeutic for multiple sclerosis. J Cell Biol2012; 199: 413–416.
39.
RudickRPolmanCCliffordD. Natalizumab: Bench to bedside and beyond. Arch Neurol. Epub ahead of print 5November2012; 1–11. DOI: 10.1001/jamaneurol.2013.598.
40.
GorelikLLernerMBixlerS. Anti-JC virus antibodies: Implications for PML risk stratification. Ann Neurol2010; 68: 295–303.
41.
Piet Mondrian, Composition Trees II, 1912.
42.
KapposLLiDCalabresiPA. Ocrelizumab in relapsing–remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial. Lancet2011; 378: 1779–1787.
43.
CohenJAColesAJArnoldDL. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet. Epub ahead of print 31October2012. DOI:10.1016/S0140-6736(12)61769-3.
44.
GoldRKapposLArnoldDLPlacebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med2012; 367: 1098–1107.
45.
FoxRJMillerDHPhillipsTPlacebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med2012; 367: 1087–1097.
46.
PlattenMYoussefSHurEM. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci U S A2009; 106: 14948–14953.
47.
StegbauerJLeeDSeubertS. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci U S A2009; 106: 14942–14947.
48.
YoussefSStüveOPatorroyoJ. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in CNS autoimmune disease. Nature2002; 420: 78–84.
49.
WaubantEPelletierDMassM. Randomized controlled trial of atorvastatin in clinically isolated syndrome: The STAyCIS study. Neurology2012; 78: 1171–1178.
LutterottiASospedraMMartinRAntigen-specific therapies in MS — Current concepts and novel approaches. J Neurol Sci2008; 274: 18–22.
52.
Sabatos-PeytonCAVerhagenJWraithDCAntigen-specific immunotherapy of autoimmune and allergic diseases. Curr Opin Immunol2010; 22: 609–615.
53.
JuryńczykMWalczakAJurewiczA. Immune regulation of multiple sclerosis by transdermally applied myelin peptides. Ann Neurol2010; 68: 593–601.
54.
Bar-OrAVollmerTAntelJ. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol2007; 64: 1407–1415.
55.
GarrenHRobinsonWKrasulováE. Phase 2b trial of a DNA vaccine encoding myelin basic protein in relapsing multiple sclerosis. Ann Neurol2008; 63: 611–620.
56.
TradtrantipLZhangHSaadounS. Anti-aquaporin-4 antibody blocker therapy for neuromyelitis optica. Ann Neurol2012; 71: 314–322.
57.
SteinmanLZamvilSSRe-engineering of pathogenic aquaporin 4-specific antibodies as molecular decoys to treat neuromyelitis optica. Ann Neurol2012; 71: 287–288.
58.
SteinmanLInverse vaccination, the opposite of Jenner’s concept, for therapy of autoimmunity. J Intern Med2010; 267: 441–451.
